Living with a retinal condition like age-related macular degeneration or diabetic macular edema can be frightening. These conditions can threaten your vision, making it vital to have reliable treatments. A large review of data looked at how biosimilar drugs compare to the original brand-name versions for these specific eye issues.
Researchers looked at several conditions, including retinal vein occlusion and polypoidal choroidal vasculopathy. They compared the results of biosimilar anti-VEGF drugs against the reference drugs. The study found no significant differences in final vision, the change in vision, or the thickness of the retina. This means the biosimilar versions performed similarly to the brand-name drugs in these tests.
Safety was also a key focus. The study found no significant differences in the number of adverse events between the two types of drugs. While the study notes that more diverse patients and longer follow-up periods would provide even more clarity, the current evidence shows these drugs are comparable in both safety and vision outcomes.
